BioSyent Profit Margin

As of the most recent data (June 2026), RX.V shows a profit margin of 17.73%. That compares with 20.9% in the prior-year period — down 15.2% year over year. That is above the sector sector average of 13.16%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RX.V's profit margin is now 17.73% (was 20.9%) — a 15.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BioSyent is outperforming or lagging.

The its sector sector average profit margin is about 13.16%. BioSyent is at 17.73%, which is higher that average. That is roughly 34.7% above the sector mean. Use the comparison chart on this page to see how RX.V stacks up against individual peers as well.

That compares with 20.9% in the prior-year period — down 15.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare BioSyent with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has BioSyent's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 17.73%) with ownership activity and broader fundamentals.